Wall Street analysts predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce earnings per share of $0.55 for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The highest EPS estimate is $0.64 and the lowest is $0.43. Teva Pharmaceutical Industries posted earnings per share of $0.93 in the same quarter last year, which indicates a negative year over year growth rate of 40.9%. The firm is expected to report its next earnings results before the market opens on Wednesday, February 13th.
On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.94 per share for the current financial year, with EPS estimates ranging from $2.80 to $3.03. For the next fiscal year, analysts expect that the firm will post earnings of $2.80 per share, with EPS estimates ranging from $2.20 to $3.30. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The company had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.54 billion. During the same quarter last year, the company posted $1.00 EPS. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year.
Several equities analysts have recently issued reports on TEVA shares. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target on the stock in a research note on Monday, October 1st. Leerink Swann upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and lifted their price target for the company from $16.00 to $24.00 in a research note on Monday, October 1st. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $27.00 in a research note on Monday, November 5th. Bank of America upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price target on the stock in a research note on Thursday, January 3rd. Finally, Wells Fargo & Co reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Friday, November 2nd. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $22.15.
Shares of TEVA traded up $0.06 during midday trading on Friday, hitting $18.82. The company’s stock had a trading volume of 4,730,574 shares, compared to its average volume of 10,099,442. Teva Pharmaceutical Industries has a one year low of $14.59 and a one year high of $25.96. The company has a debt-to-equity ratio of 1.75, a quick ratio of 0.61 and a current ratio of 0.94. The firm has a market cap of $19.08 billion, a price-to-earnings ratio of 4.79, a PEG ratio of 5.97 and a beta of 1.10.
In related news, VP Hafrun Fridriksdottir sold 1,643 shares of the business’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total transaction of $25,795.10. Following the sale, the vice president now owns 13,469 shares in the company, valued at approximately $211,463.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 2,922 shares of company stock worth $53,962 in the last 90 days. 0.43% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Quadrant Capital Group LLC lifted its holdings in Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after buying an additional 4,476 shares during the period. CWM LLC lifted its holdings in Teva Pharmaceutical Industries by 315,000.0% during the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock worth $136,000 after buying an additional 6,300 shares during the period. MAI Capital Management acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter worth about $204,000. Rehmann Capital Advisory Group lifted its holdings in Teva Pharmaceutical Industries by 8.8% during the 3rd quarter. Rehmann Capital Advisory Group now owns 9,814 shares of the company’s stock worth $211,000 after buying an additional 795 shares during the period. Finally, FNY Investment Advisers LLC lifted its holdings in Teva Pharmaceutical Industries by 989,900.0% during the 3rd quarter. FNY Investment Advisers LLC now owns 9,900 shares of the company’s stock worth $213,000 after buying an additional 9,899 shares during the period. 61.67% of the stock is currently owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.